Argenx stock trades near 52-week high as quarterly revenue reaches USD 1.5 billion

Argenx SE (ISIN NL0010832176) stock is trading at around USD 1,007.07 on Nasdaq on September 9, 2026, keeping the share price close to its 12-month high of USD 1,072.75 and reflecting strong investor confidence after reporting second-quarter 2026 revenue of USD 1.5 billion driven by its lead drug VYVGART.

Quarterly revenue of USD 1.5 billion underpins valuation

According to Investing.com on September 8, 2026, Argenx management highlighted that second-quarter 2026 revenue reached USD 1.5 billion, extending a strong growth run for VYVGART across multiple autoimmune indications including myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and seronegative myasthenia gravis.

In that discussion, Argenx emphasized that the USD 1.5 billion second-quarter 2026 revenue was supported by continued demand for VYVGART in existing indications and emerging use in additional patient groups, underscoring that the company is now generating blockbuster-level quarterly sales from its lead product.Investing.com

Analysts see upside with consensus target above current price

As MarketBeat reported on September 9, 2026, argenx SE currently carries a consensus recommendation of Moderate Buy from 24 analysts, with five rating the stock Hold, seventeen assigning Buy and two issuing Strong Buy ratings.

According to MarketBeat on September 9, 2026, the average 12-month target price among these analysts stands at USD 1,158.61, which is about 15.0 percent above the current Nasdaq opening level of USD 1,007.07 cited in the same report.

In a separate note, Benzinga reported on September 8, 2026, that Wedbush reiterated its Outperform rating on Argenx and maintained a price target of USD 1,150, signaling that at least one covering bank still sees meaningful upside from current levels despite the strong share price performance.

Stock trades close to 12-month high with rich valuation metrics

Per MarketBeat data cited on September 9, 2026, Nasdaq-listed argenx SE opened at USD 1,007.07, with a twelve-month low of USD 661.85 and a twelve-month high of USD 1,072.75; this places the current price roughly 52.2 percent above the 12-month low and 6.1 percent below the 12-month high.

The same MarketBeat snapshot notes that argenx SE has a market capitalization of about USD 63.00 billion, a price-earnings ratio of 38.67 and a PEG ratio of 1.07, indicating that while the stock trades at a high earnings multiple, expected growth in profitability supports the valuation on a price-to-earnings-growth basis.MarketBeat

Complementing the US listing, Argenx shares also trade on Euronext Brussels under the symbol ARGX.BR, where the stock closed at EUR 865.80 on September 8, 2026, down 0.41 percent on the day, and has delivered a year-to-date return of 21.43 percent against 14.15 percent for the BEL 20 index according to Yahoo Finance.

Strategic moves and upcoming shareholder meeting add context

Beyond quarterly figures, Argenx has been active on the strategic front. According to Euronext data updated in early September 2026, Argenx completed the acquisition of Forte Biosciences, Inc. on August 27, 2026, aiming to broaden its pipeline beyond VYVGART with additional immunology assets.

The same Euronext overview lists that Argenx announced an Extraordinary General Meeting of Shareholders scheduled for September 17, 2026, providing investors with a near-term corporate event that may address integration of the Forte Biosciences acquisition, capital allocation or governance topics.Euronext

Closing view on Argenx stock price

On Nasdaq, Argenx stock recently opened at USD 1,007.07 on September 9, 2026, with the US listing serving as the primary reference price in USD and positioning the shares within a narrow range below their 12-month high while analysts' average target of USD 1,158.61 suggests room for further appreciation if VYVGART-driven revenue momentum continues.

More news and analyses on Argenx stock